Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2006-10-24
2006-10-24
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S139100, C424S141100, C424S152100, C424S153100, C424S172100, C424S173100, C424S144100, C530S387100, C530S387900, C530S388100, C530S388200, C530S388220, C530S388700, C530S388730, C530S388750
Reexamination Certificate
active
07125551
ABSTRACT:
The present invention relates to methods and compositions for the prevention and treatment and prevention of immune system disorders, including cancer, AIDS, asthmatic disorders, autoimmune diseases, organ transplant rejection and chronic viral diseases such as HCV or HBV infections. The therapeutic methods of the invention comprise administering molecules that modulate the activity of 8F4, thereby modulating costimulation of T cells. The present invention further provides monoclonal antibodies against the 8F4 molecule and hybridoma cells which produce said monoclonal antibodies. Pharmaceutical compositions comprising molecules that modulate the activity of 8F4 are also provided.
REFERENCES:
patent: 2002/0164697 (2002-11-01), Coyle et al.
patent: WO 89/10398 (1989-11-01), None
patent: WO 90/04180 (1990-04-01), None
patent: WO 98/38216 (1998-09-01), None
patent: WO 99/15553 (1999-04-01), None
patent: WO 00/46240 (2000-08-01), None
Barbey et al., 1990, “DEL cell line: a “malignant histiocytosis” CD30+ t(5;6)(q35;p21) cell line.” Int J Cancer. 45(3):546-53.
Buonfiglio et al., 1999, “Characterization of a novel human surface molecule selectively expressed by mature thymocytes, activated T cells and subsets of T cell lymphomas”, Eur. J, Immunol. 29:2863-2874.
Buonfiglio et al., 2000, “The T cell activation molecule H4 and the CD28-like molecule ICOS are identical”, Eur. J, Immunol. 30:3463-3467.
Chambers and Allison, 1997, “Co-stimulation in T cell responses.” Curr Opin Immunol. 9(3):396-404. Review.
Chirgwin et al., 1979, “Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.” Biochemistry. 18(24):5294-9.
Fischer et al., 1988, “A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade non-Hodgkin's lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor beta-chain gene.” Blood. 72(1):234-40.
Freeman et al., 1993, “Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation.” Science. 262(5135):909-11.
Greenfield et al., 1998, “CD28/B7 costimulation: a review”, Crit. Rev. Immunol. 18:389-418.
Groettrup et al., 1996, “A third interferon-gamma-induced subunit exchange in the 20S proteasome.” Eur J Immunol. 26(4):863-9.
Hara et al., 1985, Human T cell activation. II. A new activation pathway used by a major T cell population via a disulfide-bonded dimer of a 44 kilodalton polypeptide (9.3 antigen). J Exp Med. 161(6):1513-24.
Kirk et al., 1997, CTLA4-lg and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A. 94(16):8789-94.
Kohler and Milstein, 1975, “Continuous cultures of fused cells secreting antibody of predefined specificity.” Nature. 256(5517):495-7.
Kroczek RA., 1993, “Southern and northern analysis.” J Chromatogr. 618(1-2):133-45. Review.
Lani r et al., 1995, CD80 (B7) and CD86 (B70) provide similar costin lory signals for T cell proliferation, cytokine production, and g neration of CTL. J Immunol. 154(1):97-105.
Lenschow et al., 1996, “CD28/B7 system of T cell costimulation”, Annu. Rev. Immunol. 14:233-258.
Linsley et al., 1992, “Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes.” J Exp Med. 176(6):1595-604.
Lucas et al., 1995, “Naive CD28-deficient T cells can initiate but not sustain an in vitro antigen-specific immune response.” J Immunol. 154(11):5757-68.
Nishioka et al., 1994, “The role of CD40—CD40 ligand interaction in human T cell-B cell collaboration.” J Immunol. 153(3):1027-36.
Redoglia et al. 1996, “Characterization of H4: a mouse T lymphocyte activation molecule functionally associated with the CD3/T cell receptor”, Eur. J. Immunol. 26:2781-2789.
Riley et al., 1997, “Intrinsic resistance to T cell infection with HIV type 1 induced by CD28 costimulation.” J Immunol. 158(11):5545-53.
Schneider et al., 1982, A one-step purification of membrane proteins using a high efficiency immunomatrix. J Biol Chem. 257(18):10766-9.
Shahinian et al., 1993, “Differential T cell costimulatory requirements in CD28-deficient mice.” Science. 261(5121):609-12.
Vogeli and Kaytes, 1987, “Amplification, storage, and replication of libraries.” Methods Enzymol. 152:407-15.
Wallace and Miyada, 1987, “Oligonucleotide probes for the screening of recombinant DNA libraries.” Methods Enzymol. 152:432-42.
Westermeier, 1997, “A Guide to Methods and Applications of DNA and Protein Separations.”Electrophoresis in Practice, VCH Verlagsgesellschaft, Weinheim, pp. 169-181 and 224-229.
Wozney, 1990, “Using purified protein to clone its gene.” Methods Enzymol. 182:738-51.
Bundersrepublik Deutschalnd
Day Jones
Gambel Phillip
Ouspenski Ilia
LandOfFree
Methods for treatment of asthmatic disorders using a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treatment of asthmatic disorders using a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treatment of asthmatic disorders using a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3616111